As only a subset of SCLC patients have long-term responses to current anti-PD-(L)1 immunotherapy a personalized approach to treatment is essential, and our findings are important in the context of this need for potential biomarkers of better or poorer outcomes with immunotherapy. Here, CD274 is linked to small cell lung carcinoma.